Constant illumination induces Alzheimer-like damages with endoplasmic reticulum involvement and the protection of melatonin

Journal of Alzheimer's Disease

Volumn 16, Issue 2, 2009, Pages 287-300

  Ling, Zhi Qun ^a,b   Tian, Qing ^a   Wang, Li ^a   Fu, Zheng Qi ^a   Wang, Xiao Chuan ^a   Wang, Qun ^a   Wang, Jian Zhi ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CHENGDU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Alzheimer's disease; Endoplasmic reticulum stress; Light illumination; Melatonin; Tau

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CYCLIC AMP DEPENDENT PROTEIN KINASE; GLUCOSE REGULATED PROTEIN 78; GLYCOGEN SYNTHASE KINASE 3; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; MELATONIN; PHOSPHOPROTEIN PHOSPHATASE 1; SUPEROXIDE DISMUTASE; TAU PROTEIN;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ORGANELLE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME REPRESSION; HORMONE BLOOD LEVEL; HORMONE METABOLISM; ILLUMINATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RIBOSOME; ROUGH ENDOPLASMIC RETICULUM; SPATIAL MEMORY; SYNAPSE; WISTAR RAT;

EID: 60349129257     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-0949     Document Type: Article

References (82)

1. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261, 6084-6089.
2. Wang JZ, Liu F (2008) Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 85, 148-175.
3. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron 13, 45-53.
4. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, R Katzman (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-580.
5. Frenkel D, Maron R, Burt DS, Weiner HL (2005) Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears β-amyloid in a mouse model of Alzheimer disease. J Clin Invest 115, 2423-2433.
6. Halverson RA, Lewis J, Frausto S, Hutton M, Muma NA (2005) Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice. J Neurosci 25, 1226-1233.
7. Mann KM, Thorngate FE, Katoh-Fukui Y, Hamanaka H, Williams DL, Fujita S, Lamb BT (2004) Independent effects of APOE on cholesterol metabolism and brain Aβ levels in an Alzheimer disease mouse model. Hum Mol Genet 13, 1959-1968.
8. Marjanska M, Curran GL, Wengenack TM, Henry PG, Bliss RL, Poduslo JF, Jr Jack CR, Ugurbil K, Garwood M (2005) Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 102, 11906-19910.
9. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421.
10. Spires TL, Hyman BT (2005) Transgenic models of Alzheimer's disease: learning from animals. NeuroRx 2, 423-437.
11. Liu RY, Zhou JN, Van Heerikhuize J, Hofman MA, Swaab DF (1999) Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab 84, 323-327.
12. Cardinali DP, Brusco LI, Liberczuk C, Furio AM (2002) The use of melatonin in Alzheimer's disease. Neuroendocrinol Lett 23, 20-23.
13. Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, Thomas R, Thal LJ, Alzheimer's Disease Cooperative Study (2003) A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 26, 893-901.
14. Asayama K, Yamadera H, Ito T, Suzuki H, Kudo Y, Endo S (2003) Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch 70, 334-341.
15. Cardinali DP, Furio AM, Reyes MP (2005) Clinical perspectives for the use of melatonin as a chronobiotic and cytoprotective agent. Ann NY Acad Sci 1057, 327-336.
16. Benitez-King G, Túnez I, Bellon A, Ortíz GG, Antón-Tay F (2003) Melatonin prevents cytoskeletal alterations and oxidative stress induced by okadaic acid in N1E-115 cells. Exp Neurol 182, 151-159.
17. Liu SJ, Wang JZ (2002) Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin. Acta Pharmacol Sin 23, 183-187.
18. Wang DL, Ling ZQ, Cao FY, Zhu LQ, Wang JZ (2004) Melatonin attenuates isoproterenol-induced Protein Kinase A over-activation and tau hyperphosphorylation in rat brain. J Pineal Res 37, 11-16.
19. Li SP, Deng YQ, Wang XC, Wang JZ (2004) Melatonin protects SH-SY5Y neuroblastoma cells from calyculin A-induced neurofilament impairment and neurotoxicity. J Pineal Res 36, 186-191.
20. Li XC, Wang ZF, Zhang JX, Wang Q, Wang JZ (2005) Effect of melatonin on calyculin A-induced tau hyperphosphorylation. Eur J Pharmacol 510, 25-30.
21. Túnez I, Muñoz Mdel C, Feijóo M, Muñoz- Castañeda JR, Bujalance I, Valdelvira ME, Montilla López P (2003) Protective melatonin effect on oxidative stress induced by okadaic acid into rat brain. J Pineal Res 34, 265-268.
22. Chyan YJ, Poeggeler B, Omar RA, Chain DG, Frangione B, Ghiso J, Pappolla MA (1999) Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid.J Biol Chem 274, 21937-21942.
23. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL, Tabaton M, Perry G (1998) Amyloid-β deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70, 2212-2215.
24. Zhu LQ, Wang SH, Ling ZQ, Wang DL, Wang JZ (2004) Effect of inhibiting melatonin biosynthesis on spatial memory retention and tau phosphorylation in rat. J Pineal Res 37, 71-77.
25. Wang S, Zhu L, Shi H, Zheng H, Tian Q, Wang Q, Liu R, Wang JZ (2007) Inhibition of melatonin biosynthesis induces neurofilament hyperphosphorylation with activation of cyclin-dependent kinase 5. Neurochem Res 32, 1329-1335.
26. Kanematsu N, Honma S, Katsuno Y, Honma K (1994) Immediate response to light of rat pineal melatonin rhythm: analysis by in vivo microdialysis. Am J Physiol 266, R1849-R1855.
27. Minneman KP, Lynch H, Wurtman RJ (1974) Relationship between environmental light intensity and retina-mediated suppression of rat pineal serotonin-N-acetyl-transferase. Life Sci 15, 1791-1796.
28. Baydaş G, Erçel E, Canatan H, Dönder E, Akyol A (2001) Effect of melatonin on oxidative status of rat brain, liver and kidney tissues under constant light exposure. Cell Biochem Funct 19, 37-41.
29. Tian Q, Lin ZQ, Wang XC, Chen J, Wang Q, Gong CX, Wang JZ (2004) Injection of okadaic acid into the Meynert nucleus basalis of rat brain induces decreased acetylcholine level and spatial memory deficit. Neuroscience 126, 277-284.
30. Bechgaard E, Lindhardt K, Martinsen L (1998) High-performance liquid chromatographic analysis of melatonin in human plasma and rabbit serum with on-line column enrichment. J Chromatogr B Biomed Sci Appl 712, 177-181.
31. Wakabayashi H, Shimada K (1986) Variation of melatonin and serotonin contents in rat pineal gland with sex and oestrous phase difference determined by high-performance liquid chromatography with fluorimetric detection. J Chromatogr 381, 21-28.
32. Zhang CE, Tian Q, Wei W, Peng JH, Liu GP, Zhou XW, Wang Q, Wang DW, Wang JZ (2008) Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus. Neurobiol Aging 29, 1654-1665.
33. Liu SJ, Zhang AH, Li HL, Wang Q, Deng HM, Netzer WJ, Xu H, Wang JZ (2003) Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J Neurochem 87, 1333-1344.
34. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K, Grundke-Iqbal I (1997) Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol 56, 70-78.
35. Tsujio I, Tanaka T, Kudo T, Nishikawa T, Shinozaki K, Grundke-Iqbal I, Iqbal K, Takeda M (2000) Inactivation of glycogen synthase kinase-3 by protein kinase Cδ: implications for regulation of tau phosphorylation. FEBS Lett 469, 111-117.
36. Liu SJ, Zhang JY, Li HL, Fang ZY, Wang Q, Deng HM, Gong CX, Grundke-Iqbal I, Iqbal K, Wang JZ (2004) Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain. J Biol Chem 279, 50078-50088.
37. Marklund S, Marklund G (1974) Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47, 469-474.
38. Rao K, Nagendra SN, Subhash MN (1995) Monoamine oxidase isoenzymes in rat brain: differential changes during postnatal development but not aging. Neurobiol Aging 16, 833-836.
39. Maurizi CP (1997) Loss of intraventricular fluid melatonin can explain the neuropathology of Alzheimer's disease. Med Hypotheses 49, 153-158.
40. Sun L, Liu SY, Zhou XW, Wang XC, Liu R, Wang Q, Wang JZ (2003) Inhibition of protein phosphatase 2A- and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats. Neuroscience 118, 1175-1182.
41. Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF (2003) Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 35,125-130.
42. Kitchigina VF, Kudina TA, Kutyreva EV, Vinogradova OS (1999) Neuronal activity of the septal pacemaker of theta rhythm under the influence of stimulation and blockade of the median raphe nucleus in the awake rabbit. Neuroscience 94, 453-463.
43. Ito T, Yamadera H, Ito R, Endo S (1999) Effects of bright light on cognitive disturbances in Alzheimer-type dementia. Nippon Ika Daigaku Zasshi 66, 229-238.
44. Skjerve A, Holsten F, Aarsland D, Bjorvatn B, Nygaard HA, Johansen IM (2004) Improvement in behavioral symptoms and advance of activity acrophase after short-term bright light treatment in severe dementia. Psychiatry Clin Neurosci 58, 343-347.
45. McCurry SM, Gibbons LE, Logsdon RG, Vitiello MV, Teri L (2005) Nighttime insomnia treatment and education for Alzheimer's disease: a randomized, controlled trial. J Am Geriatr Soc 53, 793-802.
46. Mitchell PJ, Hoese EK, Liu L, Fogg LF, Eastman CI (1997) Conflicting bright light exposure during night shifts impedes circadian adaptation. J Biol Rhythms 12, 5-15.
47. Doljansky JT, Kannety H, Dagan Y (2005) Working under daylight intensity lamp: an occupational risk for developing circadian rhythm sleep disorder? Chronobiol Int 22, 597-605.
48. Brainard GC, Lewy AJ, Menaker M, Fredrickson RH, Miller LS, Weleber RG, Cassone V, Hudson D (1988) Dose response relationship between light irradescence and the suppression of melatonin in human volunteers. Brain Res 454, 212-218.
49. Reiter RJ (1991) Neuroendocrine effects of light. Int J Biometeorol 35, 169-175.
50. Hätönen T, Alila-Johansson A, Mustanoja S, Laakso ML (1999) Suppression of melatonin by 2000-lux light in humans with closed eyelids. Biol Psychiatry 46, 827-831.
51. Matsubara E, Bryant-Thomas T, Pacheco Quinto J, Henry TL, Poeggeler B, Herbert D, Cruz-Sanchez F, Chyan YJ, Smith MA, Perry G, Shoji M, Abe K, Leone A, Grundke-Ikbal I, Wilson GL, Ghiso J, Williams C, Refolo LM, Pappolla MA, Chain DG, Neria E (2003) Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 85, 1101-1108.
52. Selmaoui B, Touitou Y (1999) Age-related differences in serum melatonin and pineal NAT activity and in the response of rat pineal to a 50-Hz magnetic field. Life Sci 64, 2291-2297.
53. Gunduz B (2002) Daily rhythm in serum melatonin and leptin levels in the Syrian hamster (Mesocricetus auratus). Comp Biochem Physiol A Mol Integr Physiol 132, 393-401.
54. Gutjahr GH, van Rensburg LJ, Malpaux B, Richter TA, Bennett NC (2004) The endogenous rhythm of plasma melatonin and its regulation by light in the highveld mole-rat (Cryptomys hottentotus pretoriae): a microphthalmic, seasonally breeding rodent. J Pineal Res 37, 185-192.
55. Sugden D (1983) Psychopharmacological effects of melatonin in mouse and rat. J Pharmacol Exp Ther 227, 587-591.
56. Jahnke G, Marr M, Myers C, Wilson R, Travlos G, Price C (1999) Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol Sci 50, 271-279.
57. Gong CX, Liu F, Grundke-Iqbal I, Iqbal K (2005) Posttranslational modifications of tau protein in Alzheimer's disease. J Neural Transm 112, 813-838.
58. Bhat RV, Budd Haeberlein SL, Avila J (2004) Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 89, 1313-1317.
59. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF (1999) Distribution of active glycogen synthase kinase 3β in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58, 1010-1019.
60. Wang JZ, Grundke-Iqbal I, Iqbal K (2007) Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 25, 59-68.
61. Andersson TP, Skold HN, Svensson SP (2003) Phosphoinositide 3-kinase is involved in Xenopus and Labrus melanophore aggregation. Cell Signal 15, 1119-1127.
62. Soto-Vega E, Meza I, Ramirez-Rodriguez G, Benitez-King G (2004) Melatonin stimulates calmodulin phosphorylation by protein kinase C. J Pineal Res 37, 98-106.
63. Song L, de Sarno P, Jope RS (2002) Central role of glycogen synthase kinase-3β in endoplasmic reticulum stress-induced caspase-3 activation. J Biol Chem 277, 44701-44708.
64. Kim AJ, Shi YY, Austin RC, Werstuck GH (2005) Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J Cell Sci 118, 89-99.
65. Srinivasan S, Ohsugi M, Liu Z, Fatrai S, Bernal-Mizrachi E, Permutt MA (2005) Endoplasmic reticulum stress-induced apoptosis is partly mediated by reduced insulin signaling through phosphatidylinositol 3-kinase/Akt and increased glycogen synthase kinase-3β in mouse insulinoma cells. Diabetes 54, 968-975.
66. Andersson TP, Svensson SP, Karlsson AM (2003) Regulation of melanosome movement by MAP kinase. Pigment Cell Res 16, 215-221.
67. 2+ disturbances, and cell death in renal epithelial cells. J Biol Chem 272, 21751-21759.
68. McCullough KD, Martindale JL, Klotz LO, Aw TY, Holbrook NJ (2001) Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol Cell Biol 21, 1249-1259.
69. Sitia R, Molteni SN (2004) Stress, protein (mis)folding, and signaling: the redox connection. Sci STKE 239, pe27.
70. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791.
71. Hernández F, Borrell J, Guaza C, Avila J, Lucas JJ (2002) Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem 83, 1529-1533.
72. Engel T, Lucas JJ, Gómez-Ramos P, Moran MA, Avila J, Hernández F (2006) Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging 27, 1258-1268.
73. Engel T, Hernández F, Avila J, Lucas JJ (2006) Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 26, 5083-5090.
74. Zhu LQ, Wang SH, Liu D, Yin YY, Tian Q, Wang XC, Wang Q, Chen JG, Wang JZ (2007) Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments. J Neurosci 27, 12211-12220.
75. Pappolla MA, Chyan YJ, Poeggeler B, Frangione B, Wilson G, Ghiso J, Reiter RJ (2000) An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J Neural Transm 107, 203-231.
76. Kennedy BP, Ziegler MG, Alford M, Hansen LA, Thal LJ, Masliah E (2003) Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease. J Neural Transm 110, 789-801.
77. Tibbles LA, Woodgett JR (1999) The stress-activated protein kinase pathways. Cell Mol Life Sci 55, 1230-1254.
78. Puig B, Gómez-Isla T, Ribé E, Cuadrado M, Torrejón-Escribano B, Dalfó E, Ferrer I (2004) Expression of stress-activated kinases c-Jun N-terminal kinase (SAPK/JNK-P) and p38 kinase (p38-P), and tau hyperphosphorylation in neurites surrounding βA plaques in APP Tg2576 mice. Neuropathol Appl Neurobiol 30, 491-502.
79. Hensley K, Floyd RA, Zheng NY, Nael R, Robinson KA, Nguyen X, Pye QN, Stewart CA, Geddes J, Markesbery WR, Patel E, Johnson GV, Bing G (1999) p38 Kinase is activated in the Alzheimer's Disease brain J Neurochem 72, 2053-2058.
80. Reynolds CH, Betts JC, Blackstock WP, Nebreda SR, Anderton BH (2000) Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun Nterminal kinase and P38, and glycogen synthase kinase-3β. J Neurochem 74, 1587-1595.
81. Reynolds CH, Utton MA, Gibb GM, Yates A, Anderton BH (1997) Stress-activated protein kinase/c-jun N-terminal kinase phosphorylates tau protein. J Neurochem 68, 1736-1744.
82. Reynolds CH, Nebreda AR, Gibb GM, Utton MA, Anderton BH (1997) Reactivating kinase/p38 phosphorylates tau protein in vitro. J Neurochem 69, 191-198.